A study explores the use of peptide receptor radionuclide therapy (PRRT) and osilodrostat for treating ectopic Cushing syndrome caused by thymic neuroendocrine neoplasms. This research contributes to understanding treatment options for this rare condition.
use of prrt and osilodrostat for ectopic cushing syndrome secondary to thymic neuroendocrine neoplasm
Original title: “Use of PRRT and osilodrostat for ectopic Cushing syndrome secondary to thymic neuroendocrine neoplasm.”